Madrigal Pharmaceuticals (MDGL) Prepaid Assets (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Prepaid Assets of $68.6 million for Q2 2026, up 17.01% year-over-year from $58.6 million in Q2 2025, and up 5.57% quarter-over-quarter from $65.0 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Prepaid Assets (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Prepaid Assets for 17 consecutive years, with $68.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Prepaid Assets rose 17.01% year-over-year to $68.6 million; the TTM figure through Jun 2026 stood at $68.6 million (up 17.01% YoY), while the FY2025 annual figure was $47.8 million, up 246.76% from the prior year.
- Prepaid Assets rose to $68.6 million in Q2 2026 per MDGL's latest filing, from $65.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $68.6 million in Q2 2026 and bottomed at $1.2 million in Q1 2022.
- Historically, Prepaid Assets has averaged $22.1 million across 5 years, with a median of $13.9 million in 2024.
- Annual changes were most pronounced in 2023 — Prepaid Assets decreased 20.46% — and 2024, when it soared 676.7%.
- Madrigal Pharmaceuticals' Prepaid Assets stood at $2.6 million in 2022, then grew by 21.39% to $3.2 million in 2023, then jumped by 337.65% to $13.8 million in 2024, then surged by 246.76% to $47.8 million in 2025, then jumped by 43.44% to $68.6 million in 2026.
- Business Quant data shows MDGL's Prepaid Assets at $68.6 million in Q2 2026, $65.0 million in Q1 2026, and $47.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.57 Mn |
| Mar 31, 2026 | 64.96 Mn |
| Dec 31, 2025 | 47.80 Mn |
| Sep 30, 2025 | 49.33 Mn |
| Jun 30, 2025 | 58.60 Mn |
| Mar 31, 2025 | 23.24 Mn |
| Dec 31, 2024 | 13.79 Mn |
| Sep 30, 2024 | 20.86 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 14.04 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | 3.18 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 2.78 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 3.81 Mn |